Invitation to Capital Markets Day on September 20

Vitrolife AB (publ) hereby invites analysts, investors, shareholders and journalists to a Capital Markets Day on September 20.

We will talk about Vitrolife’s business, which assists in making many people’s desire to have children a reality. We will give an update on the operative and financial development of the Vitrolife Group and a presentation of Vitrolife’s new acquisitions of MTG and Octax in Germany. There will be an opportunity to visit one of our production facilities and to see how some of our most important products are used.

Time
September 20, 4 pm – 7 pm.

Venue
Vitrolife’s headquarters, Gustaf Werners gata 2, 421 32 Västra Frölunda/Gothenburg.

Registration
Please inform Anita Ahlqvist that you will attend by email,
investor@vitrolife.com , or by telephone on +46 (0)31–721 80 83, no later than August 26. A light meal will be served, so please inform us of any allergies you may have. There is limited seating. The main part of the presentations will be held in Swedish.

Gothenburg, June 15, 2016

VITROLIFE AB (publ)

For further information, please contact:
Thomas Axelsson, CEO, 46 31 721 80 01
Mikael Engblom, CFO, 46 31 721 80 14

This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.

_________________________________________________________________________________________________________________

Vitrolife is an international medical device Group. Vitrolife develops, produces and markets medical devices for assisted reproduction. Work is also carried out to enable the use and handling of stem cells for therapeutic purposes

  Vitrolife has approximately 360 employees and the company's products are sold in almost 110 markets. The company is headquartered in Gothenburg, Sweden, and there are also offices in USA, Australia, France, Italy, United Kingdom, China, Japan, Hungary, Denmark and Germany. The Vitrolife share is listed on NASDAQ Stockholm, Mid Cap.

Vitrolife AB (publ), Box 9080, SE-400 92 Göteborg, Sweden. Corporate identity number 556354-3452. Tel: 46 31 721 80 00. Fax: 46 31 721 80 99. E-mail: info@vitrolife.com. Website: www.vitrolife.com/

Tags:

About Us

Vitrolife is an international medical device Group. The Fertility product area develops, produces and markets medical devices for assisted reproduction. Work is also carried out to enable the use and handling of stem cells for therapeutic purposes. Vitrolife has approximately 330 employees and the company’s products are sold in about 110 markets. The company is headquartered in Gothenburg, Sweden, and there are also offices in USA, Australia, France, Italy, United Kingdom, China, Japan, Hungary and Denmark. The Vitrolife share is listed on NASDAQ OMX Stockholm, Mid Cap.

Subscribe

Documents & Links